Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mahon

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
International Journal of Cancer|October 6, 2018
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomyAlison Y Zhang, Karen Chiam, Ygal Haupt, et al.
Therapeutic Advances in Medical Oncology|April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
JAMA|January 4, 2018
Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial, Mikael Knip, Hans K Åkerblom, et al.
The Canadian Journal of Cardiology|May 31, 2007
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan, Brenda Hemmelgarn, Raj Padwal, et al.
The Canadian Journal of Cardiology|June 13, 2008
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan, Brenda Hemmelgarn, Robert J Herman, et al.
The Canadian Journal of Cardiology|May 7, 2009
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapyNadia A Khan, Brenda Hemmelgarn, Robert J Herman, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
International Journal of Cancer|October 6, 2018
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomyAlison Y Zhang, Karen Chiam, Ygal Haupt, et al.
Therapeutic Advances in Medical Oncology|April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
JAMA|January 4, 2018
Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial, Mikael Knip, Hans K Åkerblom, et al.
The Canadian Journal of Cardiology|May 31, 2007
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan, Brenda Hemmelgarn, Raj Padwal, et al.
The Canadian Journal of Cardiology|June 13, 2008
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan, Brenda Hemmelgarn, Robert J Herman, et al.
The Canadian Journal of Cardiology|May 7, 2009
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapyNadia A Khan, Brenda Hemmelgarn, Robert J Herman, et al.
Pageof 10